Fellow's quick read · Infectious Disease
Coccidioidomycosis
IDSA 2016 · reviewed 2026-07-03
Personal study digest for a new ID fellow. Recommendations are from the cited IDSA 2016 guideline (Galgiani et al, Clin Infect Dis 2016;63:e112-46, PMID 27470238, doi:10.1093/cid/ciw360). The "What's changed since 2016" section is reviewer synthesis of newer evidence, each claim cited — not guideline text. Not a substitute for the full guideline.
In one line
Coccidioidomycosis ("Valley Fever") is a systemic dimorphic fungal infection acquired by inhalation in the endemic Southwest — most infections need no antifungal at all, but a residence/travel history plus unexplained CAP, erythema nodosum, or polyarthralgias should trigger serologic testing, and treatment is reserved for debilitating, disseminated, or high-risk disease.
When to suspect / diagnose
- Trigger: residence in or travel to the endemic Southwest (CA, AZ, NM, west TX + expanding pockets) within the prior 1–2 months, plus community-acquired pneumonia, erythema nodosum/multiforme, or symmetric arthralgias ("desert rheumatism"). Incubation is 1–4 weeks; hematogenous spread occurs weeks to months later (longer in the immunosuppressed).
- Serology first-line: EIA IgM/IgG — roughly 2x more sensitive than immunodiffusion (IDTP/IDCF) or complement fixation (CF), so used for initial screening. A positive IgM ALONE is the least reliable result and can be a false positive; repeat serology over subsequent weeks resolves ambiguity. Serologic tests may be falsely negative early — this does NOT rule out infection.
- Culture (sputum/BAL or tissue) is fastest when serology is pending or the patient is hospitalized; PCR and urine/serum antigen are less-used adjuncts, antigen mainly positive in extensive disease.
- CF antibody titer trends with disseminated risk but is NOT reliable alone for diagnosing dissemination — don't anchor on a single high titer.
- Don't over-image: if history/exam find no focal extrapulmonary complaint, skip routine bone scans/whole-body CT/MRI and lumbar puncture — image only the area a symptom points to.
Workup the fellow drives
- Confirm with EIA serology + culture; get a CF titer when dissemination is a concern (trend, don't over-interpret a single value).
- Lumbar puncture only if unusual/worsening/persistent headache, altered mental status, unexplained nausea/vomiting, or a new focal neurologic deficit — not a reflex test in every newly diagnosed patient.
- Identify host risk that changes management: high-dose steroids (≥20 mg/day prednisone ≥2 weeks), organ-transplant antirejection therapy, TNF inhibitors, HIV/CD4 <250, pregnancy (esp. 3rd trimester), diabetes, African or Filipino ancestry, or age/frailty.
Empiric & definitive therapy
| Scenario | Drug / dose / route | Duration | Strength |
|---|---|---|---|
| Mild/nondebilitating uncomplicated pneumonia | No antifungal — education, observation, reconditioning PT | Follow to resolution | Strong, low |
| Debilitating illness, extensive infiltrate, diabetes, frailty, or pregnancy risk | Fluconazole ≥400 mg PO daily (nonpregnant adults) | Until clinical/serologic resolution | Strong, low |
| Asymptomatic pulmonary nodule or cavity | No antifungal | — | Strong, low/very low |
| Symptomatic chronic cavitary pneumonia | Fluconazole or itraconazole (oral) | Until symptoms resolve; surgery if cavity persists >2 yr or recurs off therapy | Strong, moderate |
| Extrapulmonary soft tissue (non-bone) | Fluconazole or itraconazole | Until resolution | Strong, moderate |
| Bone/joint disease | Azole (fluconazole/itraconazole); AmB first if extensive/limb-threatening, then switch to azole | Prolonged, individualized | Strong, low |
| Coccidioidal meningitis | Fluconazole 400–1200 mg PO daily (no dose <400 mg); itraconazole 200 mg 2–4x/day needs closer monitoring | Lifelong — stopping → near-universal relapse | Strong, moderate |
| CM failing initial fluconazole | Higher-dose fluconazole first; else switch azole or add intrathecal AmB | Individualized | Strong, moderate |
| Very severe/rapidly progressive pulmonary or disseminated disease (incl. HSCT/SOT) | IV AmB until stabilized → transition to fluconazole | Individualized | Strong, low |
Key decisions a fellow owns
- Treat vs observe is the single most common consult question — most primary pulmonary infection resolves without antifungal; reserve treatment for debilitating illness or the host-risk features above.
- Surgical referral for: cavity persistent/symptomatic >2 years, recurrence off therapy (VATS preferred over open thoracotomy), any ruptured cavity (decortication/resection), and ALL vertebral coccidioidomycosis (surgical consult even if no immediate operative need).
- Neurosurgery early for hydrocephalus — most patients with elevated ICP will eventually need a shunt; get MRI + neurosurgical consult early rather than serial LPs indefinitely. Shunt malfunction → single-stage revision; infected shunt → remove and replace in a second, later procedure.
- Don't delay ART in HIV-positive patients over IRIS concern.
Special populations
- Pregnancy: azoles are avoided in the FIRST trimester (teratogenic) — use IV AmB (or intrathecal AmB for meningitis presenting in the 1st trimester); an azole can be considered after the first trimester. Breastfeeding is not recommended on azoles other than fluconazole. Neonates: empiric fluconazole 6–12 mg/kg/day if suspected; avoid serologic testing in the first 3 months of life (unreliable).
- HIV: treat if CD4 <250 cells/µL and continue until CD4 recovers above that threshold; at CD4 ≥250, manage as a non-HIV patient. No antifungal prophylaxis for asymptomatic HIV patients living in endemic areas; yearly serology + CXR screening in-region only.
- HSCT/SOT: fluconazole 400 mg/day (renal-adjusted) for stable disease; IV AmB for severe/rapidly progressive disease until stabilized. Reduce immunosuppression if severe (without provoking GVHD/rejection). Continue suppressive azole therapy after initial treatment to prevent relapse.
- Transplant/biologic prevention: organ-transplant recipients in the endemic area without active disease → fluconazole 200 mg/day x6–12 months. Biologic-response-modifier recipients → screen serology before starting + clinical follow-up; no routine serologic screening or prophylaxis if asymptomatic.
Duration & stopping
- Uncomplicated pulmonary disease: no fixed course — treat (if treating) until clinical and serologic resolution, individualized.
- Coccidioidal meningitis: lifelong azole — this is the guideline's clearest hard rule; relapse is near-universal off therapy.
- Chronic cavitary/bone disease: prolonged, individualized courses; surgery considered for cavities persisting >2 years.
What's changed since 2016
Reviewer synthesis — not the guideline. No newer IDSA coccidioidomycosis guideline has been published; the 2016 document remains the current, operative reference (confirmed via IDSA's practice-guideline list and PubMed, July 2026).
- Salvage options beyond fluconazole/itraconazole/AmB now exist for refractory disease — the 2016 guideline's therapeutic ceiling for azole failure was intrathecal AmB. Fosmanogepix (a Gwt1-inhibitor prodrug), used via an FDA expanded-access program, produced response in 8/11 patients with refractory coccidioidomycosis — 6/8 (75%) with coccidioidal meningitis and 2/3 with non-meningeal dissemination, over a median 208-day course (Clin Infect Dis 2026, doi:10.1093/cid/ciag271). Still investigational — not FDA-approved, expanded-access only (NCT06433128).
- Isavuconazole is now a reported off-label option for chronic pulmonary/soft-tissue coccidioidomycosis refractory to or intolerant of fluconazole/itraconazole — most patients improved, but failures were concentrated in coccidioidal meningitis (Heidari et al, Clin Infect Dis 2023;76:2196-9, PMID 36905151, doi:10.1093/cid/ciad146). Not an IDSA-endorsed first-line agent; case-series-level evidence only.
- Olorofim (orotomide, novel mechanism) has orphan-drug designation for coccidioidomycosis and showed efficacy in a phase 2b open-label salvage study that included 41 patients with Coccidioides among 202 with limited-option invasive fungal disease (Maertens et al, Lancet Infect Dis 2025, PMID 40541222, doi:10.1016/S1473-3099(25)00224-5). A dedicated phase 2 trial of olorofim specifically in early coccidioidal meningitis is planned to start in 2026 (NCT07385638) — the first prospective trial targeting this population. RECENCY-SENSITIVE: olorofim remains FDA-unapproved as of mid-2026 (2023 complete response letter); its phase 3 OASIS trial (positive topline, June 2026) was for invasive aspergillosis, not coccidioidomycosis — an FDA resubmission and any coccidioidomycosis-specific approval pathway remain separate and unconfirmed. Confirm current status before counseling patients.
- Still current / reinforced: universal azole prophylaxis for coccidioidal-endemic-region transplant recipients continues to show low breakthrough infection rates in a real-world cohort of relocating lung-transplant recipients (Goodlet et al, Transpl Infect Dis 2024, PMID 39312268, doi:10.1111/tid.14379) — supports, does not change, guideline rec 53.
- Open/unresolved: whether early empiric antifungal therapy changes outcomes in endemic-area CAP before a coccidioidal diagnosis is confirmed remains untested — the only RCT designed to answer this (FLEET-Valley Fever, fluconazole vs placebo in undifferentiated CAP) halted early for slow enrollment (72 of a larger planned cohort, only 8 met the primary pulmonary coccidioidomycosis case definition) and could not draw a conclusion (Messina et al, Contemp Clin Trials Commun 2021, PMID 34712863, doi:10.1016/j.conctc.2021.100851).
Anki cards minted this run
- Uncomplicated mild pulmonary coccidioidomycosis → observation only, no antifungal (treatment threshold).
- Coccidioidal meningitis fluconazole dosing: 400–1200 mg/day, unusually high vs standard dosing.
- Pregnancy: avoid azoles in the FIRST trimester (teratogenic) → amphotericin B instead.
- Currency: emerging salvage agents (fosmanogepix, isavuconazole, olorofim) for azole-refractory/CM disease beyond the 2016 guideline's options.
Sources: [1] Galgiani JN, et al. 2016 IDSA Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis 2016;63(6):e112-46. PMID 27470238, doi:10.1093/cid/ciw360. [2] Fosmanogepix expanded-access program for coccidioidomycosis. Clin Infect Dis 2026, doi:10.1093/cid/ciag271. [3] Heidari A, et al. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis. Clin Infect Dis 2023;76(12):2196-9. PMID 36905151, doi:10.1093/cid/ciad146. [4] Maertens JA, et al. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options. Lancet Infect Dis 2025. PMID 40541222, doi:10.1016/S1473-3099(25)00224-5. [5] NCT07385638 — Phase 2, Open-label Evaluation of Olorofim in Early Coccidioidal Meningitis (ClinicalTrials.gov). [6] Goodlet KJ, et al. Universal azole prophylaxis for prevention of coccidioidomycosis among lung transplant recipients. Transplant Infectious Disease 2024;27(1):e14379. PMID 39312268, doi:10.1111/tid.14379. [7] Messina JA, et al. FLEET-Valley Fever: a randomized, double-blind, placebo-controlled trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia. Contemp Clin Trials Commun 2021;24:100851. PMID 34712863, doi:10.1016/j.conctc.2021.100851.